Indicated in combination with filgrastim [DR:D03235] to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AX Other immunostimulants
L03AX23 Motixafortide
D12282 Motixafortide acetate (USAN) <US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Blood Products and Modifiers, Other
Motixafortide
D12282 Motixafortide acetate (USAN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Chemokine receptors
CXCR4 (CD184)
D12282 Motixafortide acetate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12282
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12282
